Our results show that Oxali renders low MHC-I–expressing PCa cells responsive to anti–PD-(L)1 therapy through transcriptional activation of the MHC-I AgPPM by NF-κB and p300/CBP, but not via the IFN-responsive TF STAT1. The gene discussed is CREBBP; the disease is posterior cortical atrophy.